title: [Expression of Blimp-1 mRNA in Bone Marrow Mononuclear Cells in Multiple Myeloma Patients and Its Clinical Significance].
abstract: OBJECTIVE
  To investigate the expression level of B lymphocyte-induced maturation protein-1(Blimp-1) mRNA in bone marrow mononuclear cells(BMMNC) of multiple myeloma(MM) patients and its clinical significance.
  
  
  METHODS
  Fluorescent quantitative real-time PCR(qRT-PCR) was used to measure Blimp-1 mRNA expression in BMMNC and flow cytometry(FCM) was performed to detect the number of malignant plasma cells in bone marrow of MM group (39 newly-diagnosed and untreated patients) and IDA group (5 IDA patients). The clinical data of all the patients' were collected, and the 39 patients in MM group were divided into 2 subgroups: in BD group 20 cases were treated with bortezomib-based regimen and in VOD group 19 patients were treated with VAD regimen. The age, sex, clinseal stage and type between the 2 subgroups were not statistically different. Blimp-1 mRNA expression level in BMMNC of MM patients was detected by qRT-PCR after 3 treatment cycles.
  
  
  RESULTS
  The expression levels of Blimp-1 mRNA in BMMNC of IDA patients and MM patients divided into 3 groups according to ISS were (0.00047±0.00027), ISS I(0.09543±0.02800), Ⅱ(0.13606±0.04162),Ⅲ (0.21202±0.03940), separately. There was statistical difference among the 4 groups(F=56.929,P<0.05) and there was significant difference between any 2 groups of these 4 groups(P<0.05). Significant positive correlation was found between Blimp-1 mRNA expression level and the number of malignant plasma cells, serum monoclonal proteins (M protein), β2-microglobulin(β2-MG), lactic dehydrogenase(LDH), C-reactive protein(CRP)(P<0.05). There was significant negative correlation between Blimp-1 mRNA and hemoglobin (Hb) level (P<0.05). After 3 cycles of chemotherapy, Blimp-1 mRNA level of patients with a >50% reduction of M protein was significantly lower than that of patients whose M protein did not decrease significantly(P<0.05). After 3 treatment cycles, Blimp-1 mRNA expression in BMMNC in BD group was significantly lower than that in VAD group [(0.02388±0.00871) vs (0.04823±0.00219), P<0.05].
  
  
  CONCLUSIONS
  The Blimp-1 mRNA expression level in BMMNC may reflect the tumor burden in MM patients, which related with ISS, and positively correlated with the malignant plasma cell number, M protein, β2-MG, LDH, CRP level, and negatively correlated with Hb. The change of Blimp-1 mRNA expression level in BMMNC relates with the extent of M protein reduction, suggesting it may be used as a marker for response to therapy. Bortezomib may have effect on malignant plasma cells by suppressing Blimp-1 mRNA expression.
authors: Department of Clinical Laboratorial Examination,The First Affiliated Hospital of Zhengzhou University; Key Laboratory of Henan Provicial Clinical Laboratorial Medicine; Department of Clinical Laboratorial Medicine of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors: Wen-Tan
authors: WT
authors: Hu
authors: Department of Clinical Laboratorial Examination,The First Affiliated Hospital of Zhengzhou University; Key Laboratory of Henan Provicial Clinical Laboratorial Medicine; Department of Clinical Laboratorial Medicine of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors: Jun-Wen
authors: JW
authors: Liu
authors: Department of Clinical Laboratorial Examination,The First Affiliated Hospital of Zhengzhou University; Key Laboratory of Henan Provicial Clinical Laboratorial Medicine; Department of Clinical Laboratorial Medicine of Zhengzhou University, Zhengzhou 450052, Henan Province, China. E-mail:xingyunerliu＠163.com.
authors: Hong-Chun
authors: HC
authors: Liu
authors: Department of Clinical Laboratorial Examination,The First Affiliated Hospital of Zhengzhou University; Key Laboratory of Henan Provicial Clinical Laboratorial Medicine; Department of Clinical Laboratorial Medicine of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors: Ting-Ting
authors: TT
authors: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001853:Bone Marrow; D001854:Bone Marrow Cells; D000069286:Bortezomib; D002097:C-Reactive Protein; D003561:Cytarabine; D003907:Dexamethasone; D005434:Flow Cytometry; D006801:Humans; D009101:Multiple Myeloma; D009194:Myeloma Proteins; D010950:Plasma Cells; D000074462:Positive Regulatory Domain I-Binding Factor 1; D012333:RNA, Messenger; D060888:Real-Time Polymerase Chain Reaction; D012097:Repressor Proteins; D014750:Vincristine
chemical_list: D009194:Myeloma Proteins; D012333:RNA, Messenger; D012097:Repressor Proteins; C085016:multiple myeloma M-proteins; D003561:Cytarabine; C087042:PRDM1 protein, human; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D002097:C-Reactive Protein; D000074462:Positive Regulatory Domain I-Binding Factor 1